-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎Edited by WuXi AppTec Content Team
Takeda today announced that its dengue vaccine, Qdenga (TAK-003), has been approved by the Indonesian National Agency for Drugs and Foodstuffs (BPOM) for use in people aged 6-45 to avoid dengue infection of any serotypeImage source: 123RF
The approval of Qdenga is based on the ongoing Phase 3 TIDES trial in patients 3 years after vaccination
[1] Takeda's QDEGA® (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved in Indonesia for Use Regardless of Prior Dengue Exposure.
Disclaimer: The WuXi AppTec content team focuses on introducing global biomedical health research progress